Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: A preliminary report

A. Hourvitz, R. Mosseri, A. Solomon, Y. Yehezkelli, J. Atsmon, Y. L. Danon, R. Koren, D. Shouval

نتاج البحث: نشر في مجلةمقالةمراجعة النظراء

35 اقتباسات (Scopus)

ملخص

A new vaccine against hepatitis B virus (HBV) infection, produced in mammalian Chinese hamster ovary (CHO) cells, contains the small (s), middle (Pre S2) and large (Pre S1) surface proteins of HBV. Three injections of a 5-μg or 10-μg dose were administered intramuscularly (i.m.) at 0, 1 and 6 months to a group of 105 young adults, who were monitored for a period of 6 months after the third injection. Seroconversion rates were 100% after the second injection of the 5-μg or 10-μg dose. Geometric mean titres of HBsAb at 1 month after the third injection were 12 156 mIU ml-1 and 13 482 mIU ml-1 in those receiving the 5-μg and 10-μg dose respectively. The vaccine was well tolerated with no significant adverse events. These preliminary results suggest that the Pre S-s recombinant vaccine, produced in mammalian cells, is highly immunogenic, leading to 100% seroconversion in the population tested after injection of only two doses of 5 μg.

اللغة الأصليةالإنجليزيّة
الصفحات (من إلى)37-42
عدد الصفحات6
دوريةJournal of Viral Hepatitis
مستوى الصوت3
رقم الإصدار1
المعرِّفات الرقمية للأشياء
حالة النشرنُشِر - يناير 1996
منشور خارجيًانعم

بصمة

أدرس بدقة موضوعات البحث “Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: A preliminary report'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا